{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:29:32Z","timestamp":1786336172958,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Due to the expansion of knowledge about genetic predispositions to breast cancer, the International Hereditary Cancer Center in Szczecin has been solicited to update the Polish ministerial guidelines for the qualification of patients who should be offered prophylactic mastectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This publication is a review of the scientific literature on the impact of TP53, PTEN, PALB2, CHEK2 pathogenic variants (PVs) predisposing to breast cancer. The number of prophylactic procedures was estimated in May 2024 based on the analysis of pedigree, clinical data and a telephone survey of unselected carriers of the Cancer Genetics Outpatient Clinics in Szczecin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The literature data justifies prophylactic mastectomy in all women who carry germline pathogenic variants in TP53, PTEN or PALB2. For CHEK2 carriers prophylactic mastectomy is only justified for women carrying a high-risk variant (i.e. carriers of protein-truncating variants with a positive breast cancer family history). We propose these changes will result in approximately 122 additional bilateral procedures and 25 unilateral procedures annually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>conclusions<\/jats:title>\n                    <jats:p>Current, evidence based data supports extending the qualification criteria for prophylactic mastectomy among TP53, PTEN, PALB and CHEK2 PV carriers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00338-x","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:35:13Z","timestamp":1780590913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are current Polish guidelines for prophylactic mastectomy sufficient?"],"prefix":"10.1186","volume":"24","author":[{"given":"Adam","family":"Stachowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Cybulski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Gronwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Huzarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"D\u0119bniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Byrski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Narod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lubi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"338_CR1","unstructured":"Polish National Cancer Registry. Piersi. 2020."},{"key":"338_CR2","unstructured":"Stefa\u0144czyk Monika R, Przemys\u0142aw M, Jakub K\u0142y\u015b, Karolina. Drohomyretska Helena. Koszty leczenia w Polsce 2023 - Raport z badania [Internet]. Krak\u00f3w; 2023. Available from: https:\/\/www.pmrmarketexperts.com."},{"key":"338_CR3","unstructured":"Ministerstwo Zdrowia Rzeczpospolitej Polskiej. Journal of Laws of the Republic of Poland [Internet]. Warszawa; Jan 9. 2019. Available from: https:\/\/isap.sejm.gov.pl\/isap.nsf\/download.xsp\/WDU20190000077\/O\/D20190077.pdf"},{"issue":"21","key":"338_CR4","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","volume":"33","author":"G Bougeard","year":"2015","unstructured":"Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, et al. Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. J Clin Oncol. 2015;33(21):2345\u201352.","journal-title":"J Clin Oncol"},{"issue":"10","key":"338_CR5","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, Magenheim R, Evans DG. Guidelines for the Li\u2013Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379\u201386.","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"338_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.ajhg.2023.02.003","volume":"110","author":"A Morra","year":"2023","unstructured":"Morra A, Mavaddat N, Muranen TA, Ahearn TU, Allen J, Andrulis IL, et al. The impact of coding germline variants on contralateral breast cancer risk and survival. Am J Hum Genet. 2023;110(3):475\u201386.","journal-title":"Am J Hum Genet"},{"key":"338_CR7","unstructured":"Adam MP, Feldman J, Mirzaa GM. PTEN Hamartoma Tumor Syndrome Synonym: PHTS. 1993."},{"issue":"1","key":"338_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/jnci\/djac188","volume":"115","author":"LAJ Hendricks","year":"2023","unstructured":"Hendricks LAJ, Hoogerbrugge N, Mensenkamp AR, Brunet J, Lleuger-Pujol R, H\u00f8berg-Vetti H, et al. Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome. JNCI: J Natl Cancer Inst. 2023;115(1):93\u2013103.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"338_CR9","doi-asserted-by":"publisher","unstructured":"Lakshika T, Ruberu M, Braun D, Parmigiani G, Biswas S. Meta-analysis of breast cancer risk for individuals with PALB2 pathogenic variants. Available from: https:\/\/doi.org\/10.1101\/2023.05.31.23290791.","DOI":"10.1101\/2023.05.31.23290791"},{"issue":"6","key":"338_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/S1470-2045(15)70142-7","volume":"16","author":"C Cybulski","year":"2015","unstructured":"Cybulski C, Klu\u017aniak W, Huzarski T, Woko\u0142orczyk D, Kashyap A, Jakubowska A, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: A prospective cohort analysis. Lancet Oncol. 2015;16(6):638\u201344.","journal-title":"Lancet Oncol"},{"issue":"9","key":"338_CR11","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1158\/1078-0432.CCR-08-3128","volume":"15","author":"T Heikkinen","year":"2009","unstructured":"Heikkinen T, K\u00e4rkk\u00e4inen H, Aaltonen K, Milne RL, Heikkil\u00e4 P, Aittom\u00e4ki K, et al. The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype. Clin Cancer Res. 2009;15(9):3214\u201322.","journal-title":"Clin Cancer Res"},{"issue":"28","key":"338_CR12","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski C, Woko\u0142orczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, et al. Risk of Breast Cancer in Women With a CHEK2 Mutation With and Without a Family History of Breast Cancer. J Clin Oncol. 2011;29(28):3747\u201352.","journal-title":"J Clin Oncol"},{"issue":"9","key":"338_CR13","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1200\/JCO.22.01239","volume":"41","author":"S Yadav","year":"2023","unstructured":"Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, et al. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023;41(9):1703\u201313.","journal-title":"J Clin Oncol"},{"issue":"2","key":"338_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1136\/jmg.2008.061697","volume":"46","author":"C Cybulski","year":"2008","unstructured":"Cybulski C, Gorski B, Huzarski T, Byrski T, Gronwald J, Debniak T, et al. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations. J Med Genet. 2008;46(2):132\u20135.","journal-title":"J Med Genet"},{"key":"338_CR15","doi-asserted-by":"crossref","unstructured":"Hini\u0107 S, Cybulski C, Van der Post RS, Vos JR, Schuurs-Hoeijmakers J, Brugnoletti F et al. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet Sci. 2024;26(5).","DOI":"10.1016\/j.gim.2024.101101"},{"issue":"10","key":"338_CR16","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1245\/s10434-021-10445-9","volume":"28","author":"M Garstka","year":"2021","unstructured":"Garstka M, Henriquez A, Kelly BN, Webster A, Khubchandani JA, Hughes K, et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers? Ann Surg Oncol. 2021;28(10):5657\u201362.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"338_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10549-013-2765-x","volume":"142","author":"SL Ingham","year":"2013","unstructured":"Ingham SL, Sperrin M, Baildam A, Ross GL, Clayton R, Lalloo F, et al. Risk-reducing surgery increases survival in BRCA1\/2 mutation carriers unaffected at time of family referral. Breast Cancer Res Treat. 2013;142(3):611\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"338_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10549-017-4476-1","volume":"167","author":"V Giannakeas","year":"2018","unstructured":"Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat. 2018;167(1):263\u20137.","journal-title":"Breast Cancer Res Treat"},{"issue":"15","key":"338_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"APM Finch","year":"2014","unstructured":"Finch APM, Lubinski J, M\u00f8ller P, Singer CF, Karlan B, Senter L, et al. Impact of Oophorectomy on Cancer Incidence and Mortality in Women With a BRCA1 or BRCA2 Mutation. J Clin Oncol. 2014;32(15):1547\u201353.","journal-title":"J Clin Oncol"},{"issue":"7","key":"338_CR20","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1200\/JCO.19.01907","volume":"38","author":"X Yang","year":"2020","unstructured":"Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. J Clin Oncol. 2020;38(7):674\u201385.","journal-title":"J Clin Oncol"},{"issue":"4","key":"338_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/cancers13040849","volume":"13","author":"A \u0141ukomska","year":"2021","unstructured":"\u0141ukomska A, Menkiszak J, Gronwald J, Tomiczek-Szwiec J, Szwiec M, Jasi\u00f3wka M, et al. Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian Cancer. Cancers (Basel). 2021;13(4):849.","journal-title":"Cancers (Basel)"},{"key":"338_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.breast.2021.02.003","volume":"56","author":"JCC Scheepens","year":"2021","unstructured":"Scheepens JCC, Veer L, van \u2019t, Esserman L, Belkora J, Mukhtar RA. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability. Breast. 2021;56:61\u20139.","journal-title":"Breast"},{"issue":"9","key":"338_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/jamaoncol.2024.2212","volume":"10","author":"V Giannakeas","year":"2024","unstructured":"Giannakeas V, Lim DW, Narod SA. Bilateral Mastectomy and Breast Cancer Mortality. JAMA Oncol. 2024;10(9):1228.","journal-title":"JAMA Oncol"},{"issue":"6","key":"338_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/SLA.0000000000000769","volume":"260","author":"OM Fayanju","year":"2014","unstructured":"Fayanju OM, Stoll CRT, Fowler S, Colditz GA, Margenthaler JA. Contralateral Prophylactic Mastectomy After Unilateral Breast Cancer. Ann Surg. 2014;260(6):1000\u201310.","journal-title":"Ann Surg"},{"issue":"3","key":"338_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/ijc.29032","volume":"136","author":"BAM Heemskerk-Gerritsen","year":"2015","unstructured":"Heemskerk-Gerritsen BAM, Rookus MA, Aalfs CM, Ausems MGEM, Coll\u00e9e JM, Jansen L, et al. Improved overall survival after contralateral risk\u2010reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: A prospective analysis. Int J Cancer. 2015;136(3):668\u201377.","journal-title":"Int J Cancer"},{"issue":"1","key":"338_CR26","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/s12935-021-02194-2","volume":"21","author":"Z Jia","year":"2021","unstructured":"Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, et al. Contralateral risk-reducing local therapy in breast cancer patients with BRCA1\/2 mutations: systemic review and meta-analysis. Cancer Cell Int. 2021;21(1):512.","journal-title":"Cancer Cell Int"},{"issue":"17","key":"338_CR27","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1200\/JCO.2013.53.6656","volume":"32","author":"J Ngeow","year":"2014","unstructured":"Ngeow J, Stanuch K, Mester JL, Barnholtz-Sloan JS, Eng C. Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations. J Clin Oncol. 2014;32(17):1818\u201324.","journal-title":"J Clin Oncol"},{"key":"338_CR28","doi-asserted-by":"crossref","unstructured":"Seweryn M, Banas T, Augustynska J, Lorenc O, Kopel J, Pluta E, et al. The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017\u20132019. Int J Environ Res Public Health. 2022;19(24).","DOI":"10.3390\/ijerph192416384"},{"key":"338_CR34","unstructured":"Central Statistical Office of Republic of Poland [Internet]. [cited 2025 Jan 8].Available from: https:\/\/stat.gov.pl\/wykres\/1.html"},{"key":"338_CR35","doi-asserted-by":"crossref","unstructured":"\u0141yszczarz B, Nojszewska E. Productivity losses and public finance burden attributable to breast cancer in Poland, 2010\u20132014. BMC Cancer. 2017;17(1):676.","DOI":"10.1186\/s12885-017-3669-7"},{"key":"338_CR31","unstructured":"NCCN. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast_risk.pdf. 2025. Breast Cancer Risk Reduction."},{"key":"338_CR32","unstructured":"NCCN. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bopp.pdf. 2025. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate."},{"key":"338_CR33","unstructured":"The General Statistic Office of Republic of Poland https:\/\/stat.gov.pl\/wykres\/1.html"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00338-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00338-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:01:41Z","timestamp":1786334501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00338-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00338-x","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"16"}}